We propose that by designing a multistage responsive nanomedicine with tunable sizes, carrying DDR1‐siRNA and SN38, enabling tumor ECM active modulation, softening the tumor and blocking cancer cell signaling to overcome MMDR in CRC and achieve a synergistic chemo‐immunotherapy effect (Figure 5A). The gene discussed is DDR1; the disease is colorectal carcinoma.